Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Involvement of the D-2 dopamine receptor in the neuroleptic-induced decrease in nigral substance P.

A Oblin, B Zivkovic, G Bartholini

    European Journal of Pharmacology
    |October 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The discriminative stimulus effects of MK-801: Generalization to other N-methyl-D-aspartate receptor antagonists.

    Journal of psychopharmacology (Oxford, England)·2012
    Same author

    SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation.

    The Journal of pharmacology and experimental therapeutics·2003
    Same author

    The preclinical pharmacologic profile of tiapride.

    European psychiatry : the journal of the Association of European Psychiatrists·2001
    Same author

    SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors.

    The Journal of pharmacology and experimental therapeutics·2001
    Same author

    Circadian organization and the role of the pineal in birds.

    Microscopy research and technique·2001
    Same author

    Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice.

    European journal of pharmacology·2000
    Same journal

    Corrigendum to "Interleukin-4 alleviate polycystic ovary syndrome through promoting the polarization of M2 type macrophages via targeting NF-κB/IκB pathway" [Eur. J. Pharmacol. (2026) 1026 178965].

    European journal of pharmacology·2026
    Same journal

    Hypericin: A potential gut microbiota-based therapeutic for postpartum depression via modulating bile acid metabolism.

    European journal of pharmacology·2026
    Same journal

    Astaxanthin inhibits platelet-mediated thrombosis via suppression of bidirectional αIIbβ3 signaling.

    European journal of pharmacology·2026
    Same journal

    Repurposing of alogliptin to mitigate experimentally-induced ulcerative colitis and its associated pulmonary injury in rats through regulating inflammatory, necroptotic, and ER stress pathways.

    European journal of pharmacology·2026
    Same journal

    Erianin ameliorates liver fibrosis through the PRDX3/NLRX1 axis.

    European journal of pharmacology·2026
    Same journal

    4-Octyl itaconate attenuates renal calculi formation by inhibiting ferroptosis and oxidative stress via the Nrf2-HO-1/SLC7A11 axis.

    European journal of pharmacology·2026
    See all related articles

    Repeated drug treatments impairing dopaminergic transmission reduced substance P in rat substantia nigra. This effect is linked to D-2 dopamine receptor function, as antagonists mimicked the reduction.

    Area of Science:

    • Neuroscience
    • Pharmacology

    Background:

    • Dopaminergic pathways are crucial for motor control and reward.
    • Substance P is a neuropeptide involved in pain and neurotransmission.
    • Dysregulation of dopaminergic systems is implicated in neurological disorders.

    Purpose of the Study:

    • To investigate the effect of dopaminergic transmission impairment on substance P levels in the substantia nigra.
    • To determine the role of specific dopamine receptor subtypes, particularly D-2, in this neurochemical modulation.

    Main Methods:

    • Repeated administration of dopaminergic drugs to rats.
    • Single administration of dopaminergic drugs to rats for comparison.
    • Measurement of substance P immunoreactivity in the substantia nigra.
    • Use of selective D-2 dopamine receptor antagonists.

    Related Experiment Videos

    Main Results:

    • Repeated, but not single, drug treatments significantly reduced substance P immunoreactivity.
    • Blockade of the D-2 dopamine receptor subtype by selective antagonists produced similar reductions.
    • These findings suggest a specific role for D-2 receptor function.

    Conclusions:

    • Repeated impairment of dopaminergic transmission leads to a decrease in substantia nigra substance P.
    • The D-2 dopamine receptor is critically involved in mediating this neurochemical change.
    • This highlights a potential mechanism relevant to dopaminergic drug therapies.